Earnings Call Summary | Co-diagnostics(CODX.US) Q3 2024 Earnings Conference
Earnings Call Summary | Co-diagnostics(CODX.US) Q3 2024 Earnings Conference
Net loss for the quarter increased to $9.7 million, or a loss of $0.32 per fully diluted share, compared to a net loss of $6.0 million, or $0.20 per fully diluted share in the prior year.The following is a summary of the Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript:
以下是Co-diagnostics, Inc. (CODX) 2024年第三季度業績發佈會的摘要：
Financial Performance:
財務表現：
Total revenue for Q3 2024 decreased to $0.6 million from $2.5 million in the same period last year.
Gross profit for the quarter decreased to $0.3 million from $2.2 million year over year.
Net loss for the quarter increased to $9.7 million, or a loss of $0.32 per fully diluted share, compared to a net loss of $6.0 million, or $0.20 per fully diluted share in the prior year.
2024年第三季度的營業收入從去年同期的250萬美元減少到60萬美元。
本季度的毛利潤從去年同期的220萬美元減少到30萬美元。
本季度的淨虧損增加至970萬美元，或每股攤薄虧損0.32美元，而去年同期的淨虧損爲600萬美元，或每股攤薄虧損0.20美元。
Business Progress:
業務進展：
Co-Diagnostics is progressing with the FDA review of its Co-Dx PCR platform for over-the-counter use.
The company is expanding international regulatory submissions and preparing for clinical evaluations in diverse markets like India and South Africa.
Engagement in global trade shows to promote the platform and readiness for manufacturing expansion in India for oligonucleotide synthesis.
Co-diagnostics正在推進其Co-Dx PCR平台的FDA審查，以便進行非處方使用。
該公司正在擴大國際監管申報，併爲印度和南非等多樣市場的臨牀評估做準備。
參與全球交易會以推廣平台，並準備在印度擴大製造業以進行寡核苷酸合成。
Opportunities:
機會：
Co-Diagnostics is targeting large unmet needs internationally with its innovative testing platforms for diseases like tuberculosis and HPV, particularly in markets like India, Africa, and South America.
The company sees potential in leveraging FDA clearance to streamline registrations across Latin American regions.
Co-diagnostics 正在通過其創新檢測平台來滿足國際上對結核病和人乳頭瘤病毒等疾病的巨大未滿足需求，特別是在印度、非洲和南美等市場。
該公司看到利用FDA批准來簡化拉丁美洲各地區註冊的潛力。
Risks:
風險：
There's uncertainty in the FDA's remaining review timeline and decisions, impacting the commercial launch and adoption of the platform in the U.S.
The company faces challenges in aligning new test developments with varied international regulatory requirements.
FDA剩餘審核時間表和決定的不確定性影響平台在美國的商業推出和採用。
該公司在將新測試開發與各種國際監管要求對齊方面面臨挑戰。
More details: Co-diagnostics IR
更多詳情：Co-diagnostics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更全面的細節，請參閱IR網站。 文章僅供投資者參考，不構成任何指導或推薦建議。
譯文內容由第三人軟體翻譯。
